BRIEF-Sanofi Says Phase 2B Study Shows duvakitug Efficacious In Ulcerative Colitis, Crohn's Disease
Teva Pharmaceutical Industries Limited Sponsored ADR 0.00% Pre
Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | 31.61 31.75 | 0.00% +0.44% Pre |
Feb 17 (Reuters) - Sanofi SA SASY.PA:
SANOFI AND TEVA’S DUVAKITUG PHASE 2B MAINTENANCE DATA DEMONSTRATED CLINICALLY MEANINGFUL DURABLE EFFICACY IN ULCERATIVE COLITIS AND CROHN’S DISEASE
DUVAKITUG WAS WELL TOLERATED AND SAFETY WAS CONSISTENT WITH THE INDUCTION STUDY
FINDINGS REINFORCE POTENTIAL OF DUVAKITUG WHICH IS IN ONGOING PHASE 3 PROGRAMS IN UC AND CD
Source text: ID:nGNX1S0ckx
Further company coverage: SASY.PA
